J B Chemicals & Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on J B Chemicals & Pharmaceuticals Ltd. from all sources in a single place.

Load latest

09 Aug 2024

1691.70

0.49%

J B Chemicals & Pharmaceuticals Results Earnings Call for Q1FY25

Conference Call with J B Chemicals & Pharmaceuticals Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.

audio

J B Chemicals & Pharmaceuticals Ltd.

09 Aug 2024

1691.70

0.49%

Corp. Note

J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Compliances-Reg. 39 (3) - Details of Loss of Certificate …

BSE India

Submission of information of loss of share certificates under Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

J B Chemicals & Pharmaceuticals Ltd.

09 Aug 2024

1691.70

0.49%

Earnings Call

J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Audio recording of Investors/analysts call with Management

pdf

J B Chemicals & Pharmaceuticals Ltd.

09 Aug 2024

1691.70

0.49%

Company Update

J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper cutting of extract of consolidated financial results for quarter ended on June 30, 2024

pdf

J B Chemicals & Pharmaceuticals Ltd.

08 Aug 2024

1691.70

0.49%

JB Chemicals & Pharma Q1 results: Net profit jumps 25% to Rs 177 cr

Business Standard

JB Chemicals & Pharmaceuticals on Thursday said its net profit increased 25 per cent year-on-year to Rs 177 crore in the first quarter ended June 30, 2024. The drug firm had reported a net profit of Rs 142 crore in the April-June period last fiscal. Total income increased to Rs 1,010 crore in the June quarter from Rs 902 crore in the year-ago period, JB Pharma said in a regulatory filing. "Our overall performance in the first quarter has been robust. We have reached a new milestone of Rs 1,000 crore in quarterly sales for the first time during any quarter, with improvement across all parameters - revenue, gross profit, operating profit and operating profit margin," CEO and Wholetime Director Nikhil Chopra stated. Strong performance in the domestic business has continued, with each of the big brand franchises witnessing market-beating growth, he added. "We expect the international business including CDMO business to pick up in the second half of the financial year. The good start .